BioCentury
ARTICLE | Financial News

Ritter amends follow-on

July 21, 2017 6:48 PM UTC

On July 17, gastrointestinal disease company Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) amended its follow-on and now plans to raise up to $11.5 million through the sale of class A and class B units. The class A units comprise a common share and three-year warrants to purchase 0.5 shares.

Investors whose purchase of class A units would result in exceeding the initial beneficial ownership limitation may purchase class B units, comprising a share of series A and warrants. ...

BCIQ Company Profiles

Ritter Pharmaceuticals Inc.